Our results demonstrate,for the first time, the remarkable efficacy of the combination of PD-L1 blockade with PARP/CHK1 inhibition and provide a strong scientific rationale for combining these modalities in clinical trials for SCLC patients. This evidence concerns the gene CD274 and small cell lung carcinoma.